Potential of Edaravone for Neuroprotection in Neurologic Diseases That Do Not Involve Cerebral Infarction

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2012 Sep 15

PMID 22977573

Citations 10

Authors

Kiyoshi Kikuchi

Ko-ichi Kawahara

Hisaaki Uchikado

Naohisa Miyagi

Terukazu Kuramoto

Tomoya Miyagi

Yoko Morimoto

Takashi Ito

Salunya Tancharoen

Naoki Miura

Kazunori Takenouchi

Yoko Oyama

Binita Shrestha

Fumiyo Matsuda

Yoshihiro Yoshida

Shinihiro Arimura

Kentaro Mera

Ko-Ichi Tada

Narimasa Yoshinaga

Ryuichi Maenosono

Yoshiko Ohno

Teruto Hashiguchi

Ikuro Maruyama

Minoru Shigemori

Affiliations

Soon will be listed here.

Abstract

Edaravone was originally developed as a potent free radical scavenger and has been widely used to treat cerebral infarction in Japan since 2001. Several free radical scavengers have been developed and some of them have progressed to clinical trials for the treatment of cerebral infarction. One such scavenger, edaravone, has been approved by the regulatory authority in Japan for the treatment of patients with cerebral infarction. Of particular interest is the ability of edaravone to diffuse into the central nervous system in various neurologic diseases. Aside from its hydroxyl radical scavenging effect, edaravone has been found to have beneficial effects on inflammation, matrix metalloproteinases, nitric oxide production and apoptotic cell death. Concordantly, edaravone has been found to have neuroprotective effects in a number of animal models of disease, including stroke, spinal cord injury, traumatic brain injury, neurodegenerative diseases and brain tumors. The proven safety of edaravone following 9 years of use as a free radical scavenger suggests that it may have potential for development into an effective treatment of multiple neurologic conditions in humans.

Citing Articles

The protective effect of Edaravone against acute renocardiac syndrome in a kidney ischemia-reperfusion model.

Bagheri Y, Dehghan M, Hejazian S, Ardalan M, Zununi Vahed S, Niknafs B J Cardiovasc Thorac Res. 2025; 16(4):243-248.

PMID: 40027361 PMC: 11866771. DOI: 10.34172/jcvtr.33077.

Edaravone attenuates neuronal apoptosis in hippocampus of rat traumatic brain injury model via activation of BDNF/TrkB signaling pathway.

Ding Y, Zhu W, Kong W, Li T, Zou P, Chen H Arch Med Sci. 2021; 17(2):514-522.

PMID: 33747286 PMC: 7959085. DOI: 10.5114/aoms.2019.89849.

Traumatic Brain Injury: Oxidative Stress and Novel Anti-Oxidants Such as Mitoquinone and Edaravone.

Ismail H, Shakkour Z, Tabet M, Abdelhady S, Kobaisi A, Abedi R Antioxidants (Basel). 2020; 9(10).

PMID: 33019512 PMC: 7601591. DOI: 10.3390/antiox9100943.

Design, synthesis and biological evaluation of edaravone derivatives bearing the -benzyl pyridinium moiety as multifunctional anti-Alzheimer's agents.

Zondagh L, Malan S, Joubert J J Enzyme Inhib Med Chem. 2020; 35(1):1596-1605.

PMID: 32779503 PMC: 7470113. DOI: 10.1080/14756366.2020.1801673.

Edaravone protects from memory impairment induced by chronic L-methionine administration.

Alzoubi K, Aburashed Z, Mayyas F Naunyn Schmiedebergs Arch Pharmacol. 2020; 393(7):1221-1228.

PMID: 31989235 DOI: 10.1007/s00210-020-01827-z.

References

Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, Urabe T . Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke. 2005; 36(10):2220-5. DOI: 10.1161/01.STR.0000182241.07096.06. View

Lapchak P, Zivin J . The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator. Exp Neurol. 2008; 215(1):95-100. DOI: 10.1016/j.expneurol.2008.09.004. View

Shuaib A, Lees K, Lyden P, Grotta J, Davalos A, Davis S . NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007; 357(6):562-71. DOI: 10.1056/NEJMoa070240. View

Nakamura T, Kuroda Y, Yamashita S, Zhang X, Miyamoto O, Tamiya T . Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke. 2007; 39(2):463-9. DOI: 10.1161/STROKEAHA.107.486654. View

van der Worp H, Kappelle L, Algra A, Bar P, Orgogozo J, Ringelstein E . The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. Neurology. 2002; 58(1):133-5. DOI: 10.1212/wnl.58.1.133. View

Itoh T, Satou T, Nishida S, Tsubaki M, Hashimoto S, Ito H . The novel free radical scavenger, edaravone, increases neural stem cell number around the area of damage following rat traumatic brain injury. Neurotox Res. 2009; 16(4):378-89. DOI: 10.1007/s12640-009-9081-6. View

Raibon E, Todd L, Moller T . Glial cells in ALS: the missing link?. Phys Med Rehabil Clin N Am. 2008; 19(3):441-59, vii-viii. DOI: 10.1016/j.pmr.2008.04.003. View

. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis. 2003; 15(3):222-9. DOI: 10.1159/000069318. View

Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H . Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008; 213(2):448-55. DOI: 10.1016/j.expneurol.2008.07.017. View

10.

Feigin V, Findlay M . Advances in subarachnoid hemorrhage. Stroke. 2006; 37(2):305-8. DOI: 10.1161/01.STR.0000200558.38774.d5. View

11.

Yagi K, Kitazato K, Uno M, Tada Y, Kinouchi T, Shimada K . Edaravone, a free radical scavenger, inhibits MMP-9-related brain hemorrhage in rats treated with tissue plasminogen activator. Stroke. 2008; 40(2):626-31. DOI: 10.1161/STROKEAHA.108.520262. View

12.

Ma L, Cao T, Kandpal G, Warren L, Hess J, Seabrook G . Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neuroblastoma cells overexpressing the familial Parkinson's disease alpha-synuclein A53T mutation. Neurochem Res. 2009; 35(1):130-42. DOI: 10.1007/s11064-009-0038-1. View

13.

de Lau L, Breteler M . Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5(6):525-35. DOI: 10.1016/S1474-4422(06)70471-9. View

14.

Takahashi R . Edaravone in ALS. Exp Neurol. 2009; 217(2):235-6. DOI: 10.1016/j.expneurol.2009.03.001. View

15.

Tosaka M, Hashiba Y, Saito N, Imai H, Shimizu T, Sasaki T . Contractile responses to reactive oxygen species in the canine basilar artery in vitro: selective inhibitory effect of MCI-186, a new hydroxyl radical scavenger. Acta Neurochir (Wien). 2002; 144(12):1305-10; discussion 1310. DOI: 10.1007/s00701-002-1020-8. View

16.

Andersson U, Wang H, Palmblad K, Aveberger A, Bloom O, Erlandsson-Harris H . High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000; 192(4):565-70. PMC: 2193240. DOI: 10.1084/jem.192.4.565. View

17.

Kabashi E, Durham H . Failure of protein quality control in amyotrophic lateral sclerosis. Biochim Biophys Acta. 2006; 1762(11-12):1038-50. DOI: 10.1016/j.bbadis.2006.06.006. View

18.

Ohta S, Iwashita Y, Takada H, Kuno S, Nakamura T . Neuroprotection and enhanced recovery with edaravone after acute spinal cord injury in rats. Spine (Phila Pa 1976). 2005; 30(10):1154-8. DOI: 10.1097/01.brs.0000162402.79482.fd. View

19.

Chirumamilla S, Sun D, Bullock M, Colello R . Traumatic brain injury induced cell proliferation in the adult mammalian central nervous system. J Neurotrauma. 2002; 19(6):693-703. DOI: 10.1089/08977150260139084. View

20.

Dohi K, Satoh K, Mihara Y, Nakamura S, Miyake Y, Ohtaki H . Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury. J Neurotrauma. 2006; 23(11):1591-9. DOI: 10.1089/neu.2006.23.1591. View